Qiagen: Slower Core Growth and Back-Half-Loaded Targets Keep Risk/Reward Balanced at Hold

Dan Leonard, an analyst from UBS, maintained the Hold rating on Qiagen. The associated price target is $52.00.

Dan Leonard has given his Hold rating due to a combination of factors tied to Qiagen’s growth profile and risk balance. While he acknowledges that products like Quantiferon and Qiastat offer meaningful expansion opportunities, he believes the company’s core operations are poised to grow more slowly than those of comparable diagnostics peers, especially after management folded the Parse acquisition into its mid-term revenue outlook, effectively trimming the underlying organic growth trajectory.

He also highlights that the company’s 2026 targets point to a back-half–loaded year, with a disproportionate share of profit expected in the second half, which in his view adds execution risk. Although Qiastat’s expanding non-respiratory test menu could modestly lift margins and earnings forecasts change only marginally after incorporating Parse, Leonard judges that the stock’s upside is not compelling versus alternatives like Biomerieux, leading him to conclude that Qiagen’s risk/reward remains finely balanced and supports a neutral, or Hold, stance.

Leonard covers the Healthcare sector, focusing on stocks such as Qiagen, IQVIA Holdings, and Agilent. According to TipRanks, Leonard has an average return of 11.4% and a 58.16% success rate on recommended stocks.

In another report released on February 7, TipRanks – xAI also downgraded the stock to a Hold with a $56.00 price target.